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Abstract
Background: Monitoring and evaluation (M&E) of HIV care and treatment programs is impacted by losses to follow-up
(LTFU) in the patient population. The severity of this effect is undeniable but its extent unknown. Tracing all lost patients
addresses this but census methods are not feasible in programs involving rapid scale-up of HIV treatment in the developing
world. Sampling-based approaches and statistical adjustment are the only scaleable methods permitting accurate
estimation of M&E indices.
Methodology/Principal Findings: In a large antiretroviral therapy (ART) program in western Kenya, we assessed the impact
of LTFU on estimating patient mortality among 8,977 adult clients of whom, 3,624 were LTFU. Overall, dropouts were more
likely male (36.8% versus 33.7%; p=0.003), and younger than non-dropouts (35.3 versus 35.7 years old; p=0.020), with
lower median CD4 count at enrollment (160 versus 189 cells/ml; p,0.001) and WHO stage 3–4 disease (47.5% versus 41.1%;
p,0.001). Urban clinic clients were 75.0% of non-dropouts but 70.3% of dropouts (p,0.001). Of the 3,624 dropouts, 1,143
were sought and 621 had their vital status ascertained. Statistical techniques were used to adjust mortality estimates based
on information obtained from located LTFU patients. Observed mortality estimates one year after enrollment were 1.7%
(95% CI 1.3%–2.0%), revised to 2.8% (2.3%–3.1%) when deaths discovered through outreach were added and adjusted to
9.2% (7.8%–10.6%) and 9.9% (8.4%–11.5%) through statistical modeling depending on the method used. The estimates 12
months after ART initiation were 1.7% (1.3%–2.2%), 3.4% (2.9%–4.0%), 10.5% (8.7%–12.3%) and 10.7% (8.9%–12.6%)
respectively.
Conclusions/Significance Abstract: Assessment of the impact of LTFU is critical in program M&E as estimated mortality
based on passive monitoring may underestimate true mortality by up to 80%. This bias can be ameliorated by tracing a
sample of dropouts and statistically adjust the mortality estimates to properly evaluate and guide large HIV care and
treatment programs.
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Introduction
In resource-rich settings such as North America and Europe,
use of antiretroviral therapy (ART) has vastly improved the
prognosis of persons living with HIV/AIDS [1–4]. Over the last
five years, international response efforts, such as the Global Fund
to fight AIDS, Tuberculosis and Malaria, World Health
Organization’s (WHO) 3-by-5 program (three million patients
under treatment by 2005) and the United States President’s
Emergency Plan for AIDS Relief (PEPFAR) [5–7], have made
great strides in increasing the number of HIV infected individuals
in resource-poor settings who have access to antiretroviral therapy.
Early data indicate that such efforts are having a dramatic impact
on the morbidity and mortality of HIV infected individuals in
resource-poor settings [8–10]. A report from the Institute of
Medicine (IOM) evaluating PEPFAR stressed the importance of
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e3843impact measures and the need to strengthen national monitoring
and evaluation systems for health programs [11].
Essential to the identification of the most effective antiretroviral
treatment (ART) delivery and cost-effective HIV management
strategies for resource-constrained settings is appropriate and
efficient monitoring and evaluation of ART care and treatment
programs. However, accurate estimates of patient survival and
other clinical outcomes have been difficult to obtain, as they are
significantly impacted by patient loss to follow-up [12,13]. These
unexplained losses may rise above 40% by twelve months in some
cases (see citation [14] and the references therein). In addition to
presenting serious clinical and operational challenges, these
statistics pose urgent questions about the validity of reported
mortality estimates and, by extension, the assessment of the
effectiveness of the underlying programs.
In the past, several approaches have been used to ascertain the
vital status of patients who have not returned to clinic. The basic
level of information gathering, and most common method utilized
in resource-poor settings, is a passive surveillance system which
relies on family and friends to report patient deaths to clinic
personnel. To obtain more comprehensive information, some
form of active patient surveillance has been used. This includes
telephone contact with the patient or close relatives and
acquaintances, home visits, reviews of obituaries, vital statistics
registries (where these are available), or a combination of the
above [8,15]. In addition, methods of statistical modeling have
been developed to overcome residual biases in the vital status data
even in the presence of patient tracing and vital status
ascertainment strategies [16].
In two seminal reports, one from the Antiretroviral Treatment
in Lower Income Countries (ART-LINC) Collaboration[17] and
one from two studies funded by the Agence Nationale de
Recherches sur le SIDA (ANRS protocols 059 and 1203) in co ˆte
d’ Ivoire, reported widely varying rates of loss to follow-up and
resulting mortality estimates, depending on whether clinical
programs used active or passive patient follow-up systems [8,15].
Their work strongly argues for the inclusion of active follow-up of
patients in HIV clinical care programs to increase clinical
surveillance and improved antiretroviral adherence as well as to
reduce ascertainment bias in mortality estimates. However, with
rapid scale-up of antiretroviral treatment programs and the
resultant burgeoning patient population under care and treatment,
census patient tracing approaches are virtually impossible for the
majority of HIV care and treatment programs in resource
constrained settings due to the cost, lack of trained personnel,
and other organizational constraints.
By comparison, attempting to trace only a statistical (random or
non-random) sample of the lost patients is feasible regardless of the
size of the patient population and is thus a scalable alternative to
census patient tracing approaches. Combined with statistical
adjustment of the information gathered, this approach will generate
much improved estimates compared to passive patient follow-up.
Methods
Objectives
The primary objective of this paper is to describe how the use of
statistical sampling techniques, coupled with medical record
infrastructure and a patient tracing program, can be used to a)
enable more accurate estimation of mortality particularly in large
HIV treatment programs, and b) identify subsets of patients who
are at higher risk of being lost to follow-up (LTFU) and who may
benefit more from active patient tracing in order to improve their
clinical care.
Participants
The Academic Model for the Prevention and Treatment of
HIV/AIDS (AMPATH). A partnership initially established
between the Moi University School of Medicine in Eldoret,
Kenya Indiana University School of Medicine and Brown Medical
School in 2001 [18]. AMPATH is a member of ART-LINC and
provided the majority of the data from the East Africa region in
the report by Braitstein, Brinkhof and colleagues [8]. AMPATH
now provides HIV care and treatment to over 50,000 adults and
children living with HIV/AIDS in 19 clinics throughout western
Kenya. Patients are managed according to National Kenyan
protocols, which are consistent with WHO guidelines. The
majority of patients receive free HIV care including basic
laboratory services and antiretroviral medicines (ARV). Clinic
visits occur monthly for all patients on ARV unless alternative
arrangements have been made with their health care provider.
Patients who are not yet eligible for treatment are seen monthly or
bi-monthly depending on their immunologic status and other
factors in their health profile. Standard paper data collection forms
are used at enrolment to the program and at each subsequent visit.
Data from these forms are entered into the AMPATH electronic
Medical Record System (AMRS) [19] by data entry technicians.
Included in this analysis are HIV-positive patients aged 18 years
and over, who were enrolled between January 1, 2005 and
January 31, 2007 at either of two clinics within the AMPATH
system where an active program for tracing patients who had
missed clinic visits was initiated. Patients were included regardless
of whether they were ART-naı ¨ve or they had initiated combina-
tion ART (CART).
Research procedures
The AMPATH Outreach Program. Active outreach to
patients who miss scheduled appointments started in January
2005 at two of the AMPATH Clinics. These were the clinics at
Moi Teaching and Referral Hospital (MTRH), an urban referral
hospital located in Eldoret, Kenya’s fifth largest city, and
Mosoriot, a rural health center which serves a catchment area of
approximately 6,000 located about 30 Km from Eldoret. This
program has now been extended to the entire AMPATH system.
Outreach workers fill out a locator card for all patients enrolling
in the clinical care program. The locator card includes contact
information and a map to the patient’s residence and is used to
find the patient in the event of a missed appointment. The AMRS
produces a daily list of patients scheduled for appointments and
patients that miss their appointment are listed for outreach based
on a three-tier triage algorithm. Adult patients on CART for less
than three months are given priority. Outreach efforts for these
patients are to commence within 24 hours of a missed appoint-
ment with a goal of locating the patient within seven days. For
patients receiving CART for over three months, outreach is
activated within seven days after a missed appointment. Individ-
uals who do not receive CART are allowed a grace period of 28
days from the missed appointment prior to initiation of outreach
activities. At the time of this study, the outreach program
maintained a standalone MS Access database that contained data
pertaining to every outreach encounter including vital status of
located patients and date of death for patients found to be
deceased. This database has since become part of the AMRS.
Definition of patient dropout. In this study, a patient is
considered to be a dropout if the patient has been declared as lost
to follow-up by the program. This happens when a patient
receiving CART has not kept a visit for more than three months or
a patient that is not receiving CART has not come to clinic for
more than six months. In addition, any patient for whom outreach
Patient Dropout and Mortality
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to follow up, is considered a dropout for the present analysis. This
includes all patients that have missed appointments that
AMPATH attempted to contact. We have not distinguished
between patients declared as lost to follow-up and patients that
missed appointments and were outreached. This is because the
loss-to-follow-up status is not known among patients that have
been outreached after a missed appointment but before they have
been declared as lost to follow-up (i.e., earlier than three months
for patients on CART or before six months for patients not
receiving CART). For this reason, dropout rates reported here are
much higher than the loss-to-follow-up rates previously reported
for the AMPATH program [10].
Ethics
All patients in the study provided locator information as
described above. This is part of the standard of care at AMPATH.
Use of these data, which were routinely collected as part of the
AMPATH care protocol, was approved by both the Indiana
University Institutional Review Board (IRB) and the Moi
University Institutional Research and Ethics Committee (IREC).
Statistical methods
Descriptive statistics were produced. Patient subgroup sizes
(e.g., gender) were compared between dropouts and non-dropouts
by chi-square tests. Continuous measures such as CD4 count were
compared via the Kruskal-Wallis test. Estimates of time until an
event (e.g., time from enrollment until CART initiation) were
produced by the method of Kaplan and Meier, with time zero
(baseline) being defined as the date of enrollment in the AMPATH
program. Comparisons of these times between dropouts and non-
dropouts were performed by the log-rank test. A Cox proportion-
al-hazards model was used to assess the impact on time to loss-to-
follow-up of a number of measures obtained from the patients
prior to dropping out. These are WHO stage, CD4 count at
enrollment, gender, age and type of clinic attended (urban versus
rural). In addition, we have stratified the analysis to account for
CART start status (i.e., CART#3 months or CART.3 months)
because this factor summarizes a number of patient and disease-
related issues that may not be captured by the other factors
considered above. These analyses were implemented with SAS
version 9.1 (SAS Institute, Cary, NC).
Statistical estimation of mortality follows methods described by
Frangakis & Rubin [20], based on the concept of ‘‘double
sampling [21]. Briefly, their method selects a random sample of
dropouts, on which active follow-up is performed and their vital
status is determined. Survival estimates are then produced as an
average of the hazard of death between dropouts and non-
dropouts weighted for the relative size of the dropout and non-
dropout group. This double sampling approach attempts to
overcome the bias that is generated when analysis is based only on
observed data (such as when only considering the vital status
information passively recorded). This bias occurs because patients
that are maintained under care are not representative of the group
that is lost to follow-up. More importantly, the authors show that
the differences in survival in these two groups cannot be accounted
for by adjusting for measurements obtained prior to dropping out.
Simple pooling of the deaths that are discovered through routine
follow-up and those detected by active patient tracing is not
sufficient and the resulting estimates from such a naı ¨ve approach
may still seriously underestimate overall mortality. By contrast, the
Frangakis & Rubin double-sampling method also corrects the
estimates that are produced when double sampling (i.e., outreach)
data are incorporated into the estimates. We implemented the
Frangakis & Rubin methodology by using software specifically
written for this analysis. This software can be provided by Drs.
Frangakis and An upon request.
Survival time. For patients that were deceased, we calculated
survival time as the time from enrollment to the date of death. For
deceased patients with missing death dates, we imputed a death
date from other patients with a known death date and matching
CD4 counts at enrollment. If no matches were found and the
patient had a baseline WHO stage, then we searched among the
deceased patients with available death dates and matching WHO
stage. We then imputed a survival time from among this subset. If
the above step found no matches, then we matched based on
available death information from patients that started CART at a
similar time from enrollment.
Censoring time. For patients who dropped out, were
double-sampled, were alive and returned to clinic, we defined
‘‘censoring time’’ to be the time from enrollment to the date of the
most recent visit after outreach. For those found alive but did not
return to clinic we imputed time from last visit (before dropout) to
last visit after outreach from observed data, matching in a similar
manner to that described for the death date above. We then added
this imputed time to the observed time from enrollment to last visit
to obtain an imputed date of last visit after outreach. Otherwise,
‘‘censoring time’’ was the time from enrollment to the end of the
study (1/31/07), the usual administrative censoring time.
Baseline CD4 and WHO stage. A CD4 count and WHO
stage measurement were considered to be a ‘‘baseline’’
measurement if the measurement were taken within 3 months
after enrollment. If there were multiple measurements during this
period, the one closest to enrollment was selected as ‘‘baseline’’.
Missing CD4 count and/or WHO stage were imputed according
to the following:
(a) If CD4 count but not WHO stage were missing, CD4 count
was imputed from among patients with similar WHO stage
and matched CART start status (i.e., CART#3 months or
CART.3 months).
(b) If WHO stage but not CD4 count were missing, WHO stage
was imputed from among those with similar CD4 (stratified
as ,200 or $200 cells/ml) and matched CART start status.
(c) If both CD4 and WHO stage were missing, imputation of
WHO stage and CD4 count was obtained from among
patients with matching CART start status.
Methods of mortality estimation. We compared four
methods for estimating mortality. The first method is the usual
passive follow-up Kaplan-Meier estimate that is based on observed
deaths only (Method 1). The mortality estimates produced by
Methods 1 would typically be those reported from passive follow-
up programs. In addition, a Kaplan-Meier estimate based on all
deaths (both those recorded passively as well as those discovered
through patient tracing) was produced (Method 2). In this method
all vital status information is pooled without consideration whether
it was obtained by passive or active follow-up efforts. These results
would be routinely reported by active-follow-up programs with no
statistical adjustment. We also produced a mortality estimate as
the weighted average of the Kaplan-Meier survival estimates
between dropout and non-dropout groups (Method 3). This
method should be an improvement compared to Methods 1 and 2
because it assigns the proper weighting (invariable higher weight)
to deaths discovered through patient outreach. This method
however has been shown by Frangakis and Rubin to be biased
[20]. The fourth method is the one proposed by Frangakis and
Rubin (Method 4). This method produces a survival estimate as a
Patient Dropout and Mortality
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dropouts and non-dropouts instead of a weighted average of the
survival. This method also weighs deaths that are observed from
outreach usually by a higher weight than passively observed
deaths. The authors showed that this method produces unbiased
estimates of patient survival.
Results
Baseline characteristics
There were 8,977 adult patients enrolled in the two participat-
ing sites between January 1, 2005 and January 31, 2007. Of these,
3,624 (40%) had missed clinic visits over this period, including
64% on CART and 36% not on CART. Outreach efforts were
initiated for 1,143 (31.5%) of these and 621 (54.3%, 17.1% overall)
were successfully located. Reasons why patients were not
contacted through the Outreach Program include insufficient or
inaccurate locator information or the patient returned to clinic
prior to the initiation of outreach procedures. Unfortunately, the
reason for not initiating outreach was not included in the outreach
database at the time. It has been added to the newer version of the
database.
Patient characteristics at enrollment into AMPATH are shown
in Table 1. Imputed data generated for the Frangakis & Rubin
analysis are not reflected in the patient characteristics data shown
in the table. Approximately 35% of the patients were male, 73% of
all patients attended Moi Teaching and Referral Hospital (the
urban clinic) and 43.6% were WHO stage 3 or 4 at enrollment.
The overall median age was 35.5 years (IQR=29.6–42.3). The
overall median CD4 count (available data only) at baseline was
183 cells/ml (IQR 75–352) and the median time from enrollment
to CART initiation was 9.9 weeks (95% CI 9.6–10.3 weeks).
Eventual dropouts were slightly more likely to be male (36.8%
versus 33.7%; p=0.003), and younger than non-dropouts (35.2
versus 35.8 years old; p=0.020). They were also sicker at baseline
compared to non-dropouts as determined by significantly lower
median CD4 count at enrollment (162 versus 201 cells/ml
respectively; p,0.001) and higher WHO stage (percent 3–4 stage
47.5% versus 41.1%; p,0.001). As a result, eventual dropouts
were initiated on CART sooner after enrollment than non-
dropouts (median time to CART 6.9 versus 12.1 weeks; p,0.001).
A smaller percent of patients attending the urban clinic ultimately
dropped out during the study compared to patients attending the
rural clinic (70.3% versus 75.0% respectively; p,0.001).
Impact of baseline factors on dropout risk and on being
successfully located
Table 2 lists the results of the Cox proportional hazards model.
The impact of a number of baseline factors on dropout was
considered based on their statistical significance in univariate
analyses. The factors that were included in the model were: male
gender (hazard ratio [HR]=1.065; p=0.005), advanced WHO
stage (stage 3 or 4 versus 1 or 2; HR=1.101; p,0.001) and CD4
count (50–200 and .200 versus ,50 cells/ml; HR=0.935;
p=0.027 and 0.918; p=0.007 respectively). All remained indepen-
dently associated with higher risk of dropout. By contrast, CART
initiation at enrollment and attendance to an urban versus a rural
clinic were not significantly associated with the chance for dropout.
We generated a dropout risk score based on the Cox
proportional hazards model presented in Table 2 and compared
this risk score between various dropout subgroups. The dropouts
for whom outreach was not attempted had a slightly higher risk
score for dropping out compared to those dropouts that were
outreached (p=0.032). By contrast, among the latter group, the
successfully located dropouts had somewhat higher risk score for
dropping out compared to the outreached dropouts that were not
successfully located (p=0.036).
Estimates of patient mortality
We present two analyses based on two definitions of ‘‘baseline’’ as
the date of enrollment and the date of ART initiation. Results from
the four methods of estimating patient mortality are shown in
Table 3 and summarized in Figures 1 and 2. With the exception of
Method 1 that involves 126 deaths discovered through routine
Table 1. Patient characteristics and comparison between dropouts and non-dropouts.
Characteristic Patient subgroup p-value
Total Dropouts Non-dropouts
N=8,977 N=3,624 N=5,353
Male Gender 0.003
N (%) 3,138 (35.0%) 1,334 (36.8%) 1,804 (33.7%)
Urban clinic ,0.001
N (%) 6,561 (73.1%) 2,547 (70.3%) 4,014 (75.0%)
Baseline WHO stage 3–4 ,0.001
N (%) 3,010
* (43.6%) 913 (53.0%) 2,097 (40.5%)
Baseline CD4 count (cells/ml) ,0.001
Median (IQR) 183 (75–352) 162 (56–325) 201 (86–367)
Age (years) 0.020
Median (IQR) 35.5 (29.6–42.3) 35.2 (29.2–42.1) 35.8 (29.9–42.4)
Time until CART start (weeks) ,0.001
Median (95% CI) 9.9 (9.6–10.3) 6.9 (6.1–7.7) 12.1 (11.7–13.4)
Frequencies were compared via Pearson’s chi-square test. Continuous factors were compared via the Kruskal-Wallis test. Median times from enrollment until CART start
were estimated via the method of Kaplan and Meier and were compared by the log-rank test. IQR=Inter-quartile range.
*Out of 6,900 total patients (5,178 non-dropouts and 1,722 dropouts) with WHO stage recorded within three months of enrollment.
doi:10.1371/journal.pone.0003843.t001
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deaths that were discovered through both patient tracing and
passive follow-up. The overall mortality 12 months after enrollment
produced by Method 1 is 1.7% (95% CI 1.3%–2.0%). The overall
one-year mortality generated by Method 2, which pools all deaths
regardless ofwhethertheywerediscovered throughactiveorpassive
follow-up, is 2.8% (2.3%–3.1%). The one-year mortality estimate
based on all deaths but stratifying according to the relative size of
the dropout and non-dropout groups (Method 3) is 9.2% (7.8%–
10.6%). Method 4, which statistically adjusts the estimate of one-
year mortality by the Frangakis & Rubin method [20] is 9.9%
(8.4%–11.5%). Mortality at one-year post ART initiation estimated
by Method 1 was 1.7% (1.3%–2.2%), revised to 3.4% (2.9%–4.0%)
by Method 2, 10.5% (8.7%–12.3%) by Method 3 and 10.7%
(8.9%–12.6%) by Method 4.
Discussion
We present data from AMPATH, a large PEPFAR-funded HIV
clinical care program in western Kenya. AMPATH has imple-
mented an active follow-up program that attempts to locate as
many patients as possible among those that have discontinued
care. Analysis of these data allows adjustment of mortality
estimates based on information obtained on patient dropouts that
were located as part of the AMPATH outreach program.
Comparison between mortality estimates reveals some interesting
results.A significantnumberofpatients miss atleastoneclinicalvisit
(40% over almost two years in our cohort). The majority of these
will be lost to follow-up. Since risk factors for patient dropout (lower
CD4 count or higher WHO stage at enrollment) are also risk factors
for mortality, estimates that do not account for patients lost to
follow-up are bound to severely underestimate the true extent of
mortality and conversely overestimate the positive impact of a care
and treatment program. This is not a novel observation. The
significance of this finding is the size of the differences in mortality
estimates produced by statistically adjusted methods. The mortality
estimate produced by relying on passive follow-up (Method 1) was
1.7% one year after enrollment in the program compared to 2.8%
when all known deaths are incorporated into the analysis (Method
2). This almost two-fold difference strongly supports inclusion of
active follow-up for at least a sample of the patient dropouts. This
has been consistently reported in similar settings [8,15,22]. Review
of the results of Methods 3 and 4 however, suggest that
incorporating active follow-up to the monitoring and evaluation
of HIV care and treatment programs is only a partial solution to the
problem.The corresponding one-yearmortality estimatesproduced
when the relative size of the dropout and non-dropout groups is
taken into account (Methods 3 and 4) are much higher than the
estimates produced by naı ¨vely pooling the information without
regard to its source (passive versus active follow-up). The one-year
mortality estimate produced by Method 3, which stratifies
according to the relative sizes of the dropout and non-dropout
groups, was 9.2% and the one produced by Method 4 was 9.9%.
These are much higher than 2.7% despite the fact that all three
estimation methods incorporated the same death information.
A further example in which unadjusted data can skew program
estimates of mortality concerns AMPATH’s contribution to a
recent ART-LINC collaboration [23], where (see entry under
‘‘Eldoret’’ in Table 1 in their paper) the six-month mortality after
start of ART is 0.7%. These data include some deaths ascertained
through active follow-up so they correspond to mortality estimates
somewhere between Method 1 and 2 in our paper. The mortality
rate estimated through Methods 3 and 4 in this study (extrapolated
from the Kaplan-Meier curves of Figure 2) is 7%. Thus, the
magnitude of bias that unadjusted data such as these can introduce
to death reporting can be significant.
Estimated mortality according to Methods 1 and 2 is
significantly different from Methods 3 and 4. These differences
Table 2. Results of the Cox proportional hazards model of
patient dropout.
Factor Hazard ratio (95% CI) P value*
Gender (male versus female) 1.065 (1.021–1.109) 0.005
WHO stage (3/4 versus 1/2) 1.101 (1.057–1.145) ,0.001
CD4 count (cells/ml)
CD4$200 cells/ml 0.918 (0.856–0.980) 0.007
50#CD4,200 cells/ml 0.935 (0.875–0.995) 0.027
CD4,50 cells/ml 1.00
ARV at first visit 0.972 (0.897–1.047) 0.970
Urban clinic 0.999 (0.924–1.076) 0.460
*Wald test.
doi:10.1371/journal.pone.0003843.t002
Table 3. Mortality estimates (%, 95% CI) at one year from enrollment and one year from ART initiation. Overall estimates based on
entire cohort.
Method Mortality since enrollment (%) Mortality since ART start (%)
Passive follow-up
1. Naı ¨ve estimate (no statistical adjustment) 1.7 (1.3–2.0) 1.7 (1.3–2.2)
Combined passive and active follow-up
2. Naı ¨ve estimate (no statistical adjustment) 2.8 (2.3–3.1) 3.4 (2.9–4.0)
3. Stratifying on dropout group
a. Kaplan Meier estimate (dropouts) 20.0 (2.6–23.5) 20.4 (2.9–26.7)
b. Kaplan-Meier estimate (non-dropouts) 2.2 (1.8–16.6) 2.3 (1.7–18.0)
c. Weighted Kaplan Meier estimate* 9.2 (7.8–10.6) 10.5 (8.7–12.3)
4. Based on Frangakis & Rubin method 9.9 (8.4–11.5) 10.7 (8.9–12.6)
*Combined estimates were produced as a weighted average of the individual (dropout versus non-dropout) estimates, taking into account the relative size of the two
groups.
doi:10.1371/journal.pone.0003843.t003
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pronounced as shown in Figures 1 and 2. The reason for this
divergence with time is that a higher proportion of late deaths is
established through outreach and is thus up-weighted by the
statistical methods. This accelerates mortality increases in the
statistically adjusted survival curves. The reason for the differences
in one-year mortality estimates between Methods 1 and 2 can be
further elucidated by inspection of the results in Table 2. Patients
that ultimately dropped out were more frequently men with more
advanced disease at enrollment as determined by their higher
WHO stage. This implies that the subset of patients that were not
lost to follow-up is not representative of the entire patient
population. Thus, any estimates generated by patients under
observation will be biased. The disparity between Method 2 and
Methods 3 and 4 is due to the fact that while 126 deaths were
observed among 5,363 non-dropouts, 124 deaths were observed
among the 621 patient dropouts that were successfully located by
outreach. Thus, mortality among dropouts is much higher and
consequently simple pooling of the information results in a
significant underestimate of the overall mortality. This observation
Figure 1. Kaplan-Meier estimates of patient survival based on methods described in Table 3. Time is in months since enrollment.
doi:10.1371/journal.pone.0003843.g001
Figure 2. Kaplan-Meier estimates of patient survival based on methods described in Table 3. Time is in months since start of CART.
doi:10.1371/journal.pone.0003843.g002
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follow-up to a care and treatment program will have very limited
value for estimating mortality unless monitoring and evaluation of
resulting data is accompanied by appropriate statistical adjust-
ment.
The impression from mortality estimation adjustments one year
after ART initiation is similar. The naı ¨ve estimate produced by
Method 1 is 1.7%, revised to 3.4% when all deaths are pooled
(Method 2), and revised further to 10.5% and 10.7% by using
statistical adjustment (Methods 3 and 4 respectively). The
mortality one year after ART is slightly higher than the estimate
obtained one year after enrollment because a sizable proportion of
the patient population did not require CART at entry because of
less advanced disease and thus had lower risk of death during that
period. By contrast, patients requiring ART had more advanced
disease (a prerequisite for being eligible for treatment) and, at least
in the short term, higher risk of death.
To further understand the impact of dropout on estimates of
mortality, we refer to ANRS protocols 059 and 1203, both
initiated prior to the wide availability of CART [15]. In that study,
the investigators implemented progressively more intensive patient
outreach methods to locate as many of the lost patients as possible.
Each successive round of patient tracing located a larger
proportion of patients and resulted in progressively higher one-
year mortality estimates. The estimated one-year mortality rate
increased from 10.5%, based on passive follow-up when only 59%
of dropouts were accounted for, to 12.9% when 64% of dropouts
were accounted for. With the most intensive follow-up procedures,
81% of dropouts were accounted for, resulting in a one-year
mortality estimate of 19.6%. Their analyses did not include any
statistical adjustment for the dropouts that were not accounted for
even through the most intensive outreach efforts, so the suggestion
is that, had the deaths discovered through outreach been weighed
appropriately, the true one-year mortality rate might have been
higher still. The impression from this report is that even active
follow-up programs that successfully locate a large proportion of
their dropout patients may produce inaccurate estimates of the
true mortality of their cohort unless some statistical adjustment is
used.
Our results have both similarities with as well as important
deviations from published reports in similar settings. The results
from Method 1 are similar to the mortality estimate of 2.3% one
year after CART initiation in a ‘‘passive follow-up cohort’’
reported by Braitstein, Brinkhof and colleagues from the ART-
LINC collaboration [8]. The 95% confidence interval from that
report (1.5%–3.2%) covers the estimate of 1.7% mortality at one
year after CART initiation produced by Method 1. The one-year
mortality estimate of 3.4% produced by simple pooling of dropout
and non-dropout death information (Method 2) is lower than their
one-year mortality estimate of 6.4% generated from active follow-
up programs. The reason for this may be that the active follow-up
programs in ART-LINC successfully located a much higher
proportion of dropouts than the one implemented by AMPATH
(which also provided data for that report as part of the ART-LINC
collaboration). As previously reported, patients that are harder to
find may have higher risk of death [15]. Thus, it is expected that
the pooled estimator of mortality that was derived from the smaller
proportion of patient dropouts that were outreached and located
by AMPATH, likely seriously underestimates true mortality.
When adjusting for the relative size of the dropout and non-
dropout subgroups, the resulting mortality estimates one year after
enrollment (9.2% and 9.9% produced by Methods 3 and 4
respectively) and one year after CART initiation (10.5% and
10.7%), are significantly higher than the one-year mortality
estimates obtained from the ART-LINC active follow-up pro-
grams. The reason for this likely is that not every patient lost from
observation was accounted for by the ART-LINC active follow-up
programs (personal consultation with Drs. Braitstein and Brin-
khof). Thus, simple pooling of death data, even from programs
such as ART-LINC, that follow-up a large proportion of their
dropout patients, may still produce biased results. Since the
publication of their article, the ART-LINC collaborators have
updated and re-analyzed their data by relying on programs with
more successful active follow-up and have produced higher one-
year mortality estimates more in line with our statistically adjusted
ones [24].
Limitations
There are several limitations in our study. The most important
one is that the Frangakis & Rubin method we used to produce the
adjustment of one-year mortality estimates assumes that a random
sample was selected among the dropout patients and everyone
from that sample was located. By contrast, AMPATH attempted
to locate 1,143 patients out of the 3,624 dropouts (31.5%) of whom
621 were successfully located (54.3% of the outreached patients or
17.1% overall). We have made the tacit assumption that the group
of patients that was outreached and the subgroup that was
successfully located were both representative of the entire dropout
population. The ANRS 059/1203 study results [15] suggest that
harder to locate AMPATH patients may have been at higher risk
of death and that difficulties in locating some patients may reflect
latent subpopulations among the dropouts. It is thus possible that
our mortality estimates may still underestimate the true mortality
rate since the dropouts that were not accounted for may have
higher risk of death than the dropouts that were located. As
reported in the Results Section, the dropouts that were not
outreached had a slightly higher risk score for dropping out
compared to those dropouts that were outreached. Since the
factors entering in the development of that score are also factors
associated with poor patient outcome, this difference in risk for
dropout may imply that mortality was underestimated by the
AMPATH data. By contrast, the successfully located dropouts had
somewhat higher risk score for dropping out compared to the
outreached dropouts that were not successfully located. This
observation implies that the mortality estimates based on patients
under observation and successfully located dropouts might have
overestimated mortality. Given these observations, we expect that
the statistical estimates of mortality presented earlier, represent a
largely accurate reflection of the true mortality rate.
Our findings lead to the inescapable conclusion that both active
follow-up and appropriate statistical modeling must be employed
in combination to account for measurable and non-measurable
factors affecting mortality. With rapid scale-up of HIV care and
treatment programs, census approaches that canvass all lost
patients (such as those reported by Anglaret and colleagues [15]
and Bisson et al. [22], from cohorts of 545 and 410 patients
respectively) are inconceivable for large cohorts following tens of
thousands of patients. Even in the rare cases where this is
attempted, the resulting estimates would be biased since invariably
a large portion of patients lost to follow-up will not be located.
Thus, tracing a random sample of the dropouts and adjusting the
resulting estimates statistically is the only viable way to monitor
and evaluate increasingly large antiretroviral programs as rapid
treatment scale-up continues in Africa and the developing world.
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